AUGUST 25, 2006 Word on the Street Merriman Curhan Cuts Corcept Therapeutics to Neutral From Standard & Poor's Equity Research Merriman Curhan downgraded Corcept Therapeutics (CORT) to neutral, after the company reported disapointing results from a trial of Corlux in treatment of Psychotic Major Depression (PMD). III trial of Corlux showed a 30.5% response rate for Corlux and a 28.6% response rate for the placebo. McAllister thinks the probability of success for Corlux to treat PMD is ...
Click Here to View the Entire Article
